🇺🇸 FDA
Pipeline program

CD19/CD20 Dual-CAR-T cells

HXYT-012

Phase 1 mab on_hold

Quick answer

CD19/CD20 Dual-CAR-T cells for B-cell Non-Hodgkin's Lymphoma is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
B-cell Non-Hodgkin's Lymphoma
Phase
Phase 1
Modality
mab
Status
on_hold

Clinical trials